Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The results from a prospective, phase III clinical study of extended treatment with 5 years of letrozole compared to 2 to 3 years of letrozole
Interim results from a phase II study with and ATR inhibitor ceralasertib
Results of the GETUG/AFU VESPER V05 study
The results from the studies conducted in patients with human papillomavirus associated malignancies
Findings from a randomised, open-label, phase II study
FDA also approved the Oncomine Dx Target Test as a companion diagnostic device
Findings from a first-in-human phase I/II study that evaluated subcutaneous, highly selective and potent bispecific antibody targeting CD3 and CD20
Findings from a large, multicentre, retrospective cohort of patients with advanced cancer
An increased risk of sudden or cardiac death
The results from the SAFRON II study of single-fraction versus multifraction stereotactic ablative body radiotherapy
MASCC Survivorship Study Group points to evidence availability for telemedicine interventions only in addressing the psychosocial and physical effects of cancer
The results of the MAST study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
